Table 1.
Demographic and tumor-related characteristics of the study population: age, race, AJCC pathologic stage, hormone receptor status, and time from completion of trastuzumab (when applicable)
| Characteristic | Treatment-naïve HER2pos IBC (n = 22) | HER2pos IBC treated with T + C (n = 65) | |
|---|---|---|---|
| Neoadjuvant (n = 40) | Adjuvant (n = 25) | ||
| Age, years, mean ± standard error | 56.8 ± 3.1 | 45.9 ± 2.1 | 57.2 ± 2.6 |
| Age, years, range | 36–88 | 24–81 | 28–85 |
| Race/ethnicity, number (%) | |||
| Caucasian | 17 (77.3) | 35 (87.5) | 19 (76.0) |
| African-American | 2 (9.1) | 3 (7.5) | 4 (16.0) |
| Asian | 2 (9.1) | 1 (2.5) | 0 (0) |
| Hispanic | 1 (4.5) | 1 (2.5) | 2 (8.0) |
| AJCC stage at diagnosisa, number (%) | |||
| Stage 1 | 14 (63.6) | 0 (0) | 6 (24.0) |
| Stage 2 | 6 (27.3) | 21 (52.5) | 15 (60.0) |
| Stage 3 | 2 (9.1) | 19 (47.5) | 4 (16.0) |
| Hormone receptor status, number (%) | |||
| ER/PRpos | 12 (54.5) | 18 (45.0) | 11 (44.0) |
| ER/PRneg | 10 (45.5) | 22 (55.0) | 14 (56.0) |
| Time from completion of trastuzumab to study enrollment, number (%) | |||
| <6 months | 18 (45.0) | 10 (40.0) | |
| ≥6 months | 22 (55.0) | 15 (60.0) | |
aFor neoadjuvant cohort, AJCC clinical stage is shown. HER2 pos Human epidermal growth factor receptor overexpressing, IBC invasive breast cancer, T + C trastuzumab and chemotherapy, AJCC American Joint Committee on Cancer, ER estrogen receptor, PR progesterone receptor